| Id |
Subject |
Object |
Predicate |
Lexical cue |
| SS1_23074402_0_0 |
0-41 |
expanded |
denotes |
Epidermal Growth Factor Receptor Mutation |
| SS2_23074402_0_0 |
43-47 |
abbr |
denotes |
EGFR |
| SS1_23074402_0_1 |
102-127 |
expanded |
denotes |
Tyrosine Kinase Inhibitor |
| SS2_23074402_0_1 |
129-132 |
abbr |
denotes |
TKI |
| SS1_23074402_2_0 |
256-284 |
expanded |
denotes |
Medical Advisory Secretariat |
| SS2_23074402_2_0 |
286-289 |
abbr |
denotes |
MAS |
| SS1_23074402_3_0 |
416-435 |
expanded |
denotes |
Cancer Care Ontario |
| SS2_23074402_3_0 |
437-440 |
abbr |
denotes |
CCO |
| SS1_23074402_4_0 |
768-811 |
expanded |
denotes |
Provincial Expert Panel on Pharmacogenetics |
| SS2_23074402_4_0 |
813-817 |
abbr |
denotes |
PEPP |
| SS1_23074402_6_0 |
992-1027 |
expanded |
denotes |
Technology Assessment Collaborative |
| SS2_23074402_6_0 |
1029-1034 |
abbr |
denotes |
THETA |
| SS1_23074402_6_1 |
1354-1418 |
expanded |
denotes |
Evidence-Based AnalysisEpidermal Growth Factor Receptor Mutation |
| SS2_23074402_6_1 |
1420-1424 |
abbr |
denotes |
EGFR |
| SS1_23074402_6_2 |
1479-1504 |
expanded |
denotes |
Tyrosine Kinase Inhibitor |
| SS2_23074402_6_2 |
1506-1509 |
abbr |
denotes |
TKI |
| SS1_23074402_8_0 |
1839-1871 |
expanded |
denotes |
epidermal growth factor receptor |
| SS2_23074402_8_0 |
1873-1877 |
abbr |
denotes |
EGFR |
| SS1_23074402_8_1 |
1958-1984 |
expanded |
denotes |
tyrosine kinase inhibitors |
| SS2_23074402_8_1 |
1986-1990 |
abbr |
denotes |
TKIs |
| SS1_23074402_8_2 |
2067-2093 |
expanded |
denotes |
non-small cell lung cancer |
| SS2_23074402_8_2 |
2095-2100 |
abbr |
denotes |
NSCLC |
| SS1_23074402_14_0 |
2803-2825 |
expanded |
denotes |
adenosine triphosphate |
| SS2_23074402_14_0 |
2827-2830 |
abbr |
denotes |
ATP |
| SS1_23074402_14_1 |
2861-2876 |
expanded |
denotes |
tyrosine kinase |
| SS2_23074402_14_1 |
2878-2880 |
abbr |
denotes |
TK |
| SS1_23074402_21_0 |
3900-3925 |
expanded |
denotes |
polymerase chain reaction |
| SS2_23074402_21_0 |
3927-3930 |
abbr |
denotes |
PCR |
| SS1_23074402_26_0 |
4793-4834 |
expanded |
denotes |
amplification refractory mutations system |
| SS2_23074402_26_0 |
4836-4840 |
abbr |
denotes |
ARMS |
| SS1_23074402_30_0 |
5408-5433 |
expanded |
denotes |
progression-free survival |
| SS2_23074402_30_0 |
5435-5438 |
abbr |
denotes |
PFS |
| SS1_23074402_30_1 |
5441-5465 |
expanded |
denotes |
objective response rates |
| SS2_23074402_30_1 |
5467-5470 |
abbr |
denotes |
ORR |
| SS1_23074402_30_2 |
5473-5489 |
expanded |
denotes |
overall survival |
| SS2_23074402_30_2 |
5491-5493 |
abbr |
denotes |
OS |
| SS1_23074402_30_3 |
5500-5515 |
expanded |
denotes |
quality of life |
| SS2_23074402_30_3 |
5517-5520 |
abbr |
denotes |
QoL |
| SS1_23074402_41_0 |
7383-7408 |
expanded |
denotes |
progression-free survival |
| SS2_23074402_41_0 |
7410-7413 |
abbr |
denotes |
PFS |
| SS1_23074402_41_1 |
7416-7439 |
expanded |
denotes |
Objective response rate |
| SS2_23074402_41_1 |
7441-7444 |
abbr |
denotes |
ORR |
| SS1_23074402_41_2 |
7447-7463 |
expanded |
denotes |
overall survival |
| SS2_23074402_41_2 |
7465-7467 |
abbr |
denotes |
OS |
| SS1_23074402_41_3 |
7470-7485 |
expanded |
denotes |
quality of life |
| SS2_23074402_41_3 |
7487-7490 |
abbr |
denotes |
QoL |
| SS1_23074402_43_0 |
7842-7887 |
expanded |
denotes |
Response Evaluation Criteria in Solid Tumours |
| SS2_23074402_43_0 |
7889-7895 |
abbr |
denotes |
RECIST |
| SS1_23074402_47_0 |
8595-8617 |
expanded |
denotes |
Iressa Pan Asian Study |
| SS2_23074402_47_0 |
8619-8624 |
abbr |
denotes |
IPASS |
| SS1_23074402_47_1 |
8753-8765 |
expanded |
denotes |
Hazard ratio |
| SS2_23074402_47_1 |
8767-8769 |
abbr |
denotes |
HR |
| AE1_23074402_0_0 |
SS1_23074402_0_0 |
SS2_23074402_0_0 |
abbreviatedTo |
Epidermal Growth Factor Receptor Mutation,EGFR |
| AE1_23074402_0_1 |
SS1_23074402_0_1 |
SS2_23074402_0_1 |
abbreviatedTo |
Tyrosine Kinase Inhibitor,TKI |
| AE1_23074402_14_0 |
SS1_23074402_14_0 |
SS2_23074402_14_0 |
abbreviatedTo |
adenosine triphosphate,ATP |
| AE1_23074402_14_1 |
SS1_23074402_14_1 |
SS2_23074402_14_1 |
abbreviatedTo |
tyrosine kinase,TK |
| AE1_23074402_21_0 |
SS1_23074402_21_0 |
SS2_23074402_21_0 |
abbreviatedTo |
polymerase chain reaction,PCR |
| AE1_23074402_26_0 |
SS1_23074402_26_0 |
SS2_23074402_26_0 |
abbreviatedTo |
amplification refractory mutations system,ARMS |
| AE1_23074402_2_0 |
SS1_23074402_2_0 |
SS2_23074402_2_0 |
abbreviatedTo |
Medical Advisory Secretariat,MAS |
| AE1_23074402_30_0 |
SS1_23074402_30_0 |
SS2_23074402_30_0 |
abbreviatedTo |
progression-free survival,PFS |
| AE1_23074402_30_1 |
SS1_23074402_30_1 |
SS2_23074402_30_1 |
abbreviatedTo |
objective response rates,ORR |
| AE1_23074402_30_2 |
SS1_23074402_30_2 |
SS2_23074402_30_2 |
abbreviatedTo |
overall survival,OS |
| AE1_23074402_30_3 |
SS1_23074402_30_3 |
SS2_23074402_30_3 |
abbreviatedTo |
quality of life,QoL |
| AE1_23074402_3_0 |
SS1_23074402_3_0 |
SS2_23074402_3_0 |
abbreviatedTo |
Cancer Care Ontario,CCO |
| AE1_23074402_41_0 |
SS1_23074402_41_0 |
SS2_23074402_41_0 |
abbreviatedTo |
progression-free survival,PFS |
| AE1_23074402_41_1 |
SS1_23074402_41_1 |
SS2_23074402_41_1 |
abbreviatedTo |
Objective response rate,ORR |
| AE1_23074402_41_2 |
SS1_23074402_41_2 |
SS2_23074402_41_2 |
abbreviatedTo |
overall survival,OS |
| AE1_23074402_41_3 |
SS1_23074402_41_3 |
SS2_23074402_41_3 |
abbreviatedTo |
quality of life,QoL |
| AE1_23074402_43_0 |
SS1_23074402_43_0 |
SS2_23074402_43_0 |
abbreviatedTo |
Response Evaluation Criteria in Solid Tumours,RECIST |
| AE1_23074402_47_0 |
SS1_23074402_47_0 |
SS2_23074402_47_0 |
abbreviatedTo |
Iressa Pan Asian Study,IPASS |
| AE1_23074402_47_1 |
SS1_23074402_47_1 |
SS2_23074402_47_1 |
abbreviatedTo |
Hazard ratio,HR |
| AE1_23074402_4_0 |
SS1_23074402_4_0 |
SS2_23074402_4_0 |
abbreviatedTo |
Provincial Expert Panel on Pharmacogenetics,PEPP |
| AE1_23074402_6_0 |
SS1_23074402_6_0 |
SS2_23074402_6_0 |
abbreviatedTo |
Technology Assessment Collaborative,THETA |
| AE1_23074402_6_1 |
SS1_23074402_6_1 |
SS2_23074402_6_1 |
abbreviatedTo |
Evidence-Based AnalysisEpidermal Growth Factor Receptor Mutation,EGFR |
| AE1_23074402_6_2 |
SS1_23074402_6_2 |
SS2_23074402_6_2 |
abbreviatedTo |
Tyrosine Kinase Inhibitor,TKI |
| AE1_23074402_8_0 |
SS1_23074402_8_0 |
SS2_23074402_8_0 |
abbreviatedTo |
epidermal growth factor receptor,EGFR |
| AE1_23074402_8_1 |
SS1_23074402_8_1 |
SS2_23074402_8_1 |
abbreviatedTo |
tyrosine kinase inhibitors,TKIs |
| AE1_23074402_8_2 |
SS1_23074402_8_2 |
SS2_23074402_8_2 |
abbreviatedTo |
non-small cell lung cancer,NSCLC |
